ICON6 is a randomised three-arm, three stage, double-blind, placebo-controlled multi-centre Gynaecologic Cancer InterGroup (GCIG) phase III trial.
ICON6 is designed to evaluate the safety and efficacy of platinum-based chemotherapy in combination with cediranib in women with platinum-sensitive relapsed ovarian cancer . Cediranib is an oral targeted small molecule inhibitor of a key signalling molecule Vascular Endothelial Growth Factor (VEGF) which is an oral inhibitor of tyrosine kinase (TK) activity and acts through blockade of the TK receptor. Cediranib (AZD2171) will be administered during platinum-based chemotherapy only (concurrent cediranib), or given during chemotherapy and continued as single agent maintenance therapy (concurrent and maintenance cediranib).
Final Progression Free Survival analysis presented at The European Cancer Congress (ECCO 17 - ESMO 38 - ESTRO 32) 2013
The ICON6 Chief Investigator Professor Jonathan Ledermann presented the results of the final Progression Free Survival analysis at The European Cancer Congress in Amsterdam on 30th September 2013. The full abstract is available at the link below, just enter "ICON6" into the field labelled 'Abstract Title' and then click the 'Search' button to find the abstract.
ICON6 was selected for inclusion in The European Cancer Congress media programme. The full press release is available at the link below:
A video of the ICON6 Chief Investigator Professor Jonathan Ledermann presenting the Progression Free Survival results of the ICON6 trial to the media is also available at the link below: